These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2292530)

  • 41. A multicentric, open label, randomised, postmarketing efficacy study comparing multidose of lincomycin hydrochloride capsule 500 mg with multidose cefpodoxime proxetil tablet 200 mg in patients with tonsillitis, sinusitis.
    Kothadiya A
    J Indian Med Assoc; 2012 Aug; 110(8):580-3. PubMed ID: 23741829
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of cefpodoxime proxetil and cefixime in the treatment of acute otitis media in infants and children. Otitis Study Group.
    Asmar BI; Dajani AS; Del Beccaro MA; Mendelman PM
    Pediatrics; 1994 Dec; 94(6 Pt 1):847-52. PubMed ID: 7971000
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cefpodoxime proxetil: dosage, efficacy and tolerance in adults suffering from respiratory tract infections.
    Safran C
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():93-101. PubMed ID: 2292535
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical trials of cefpodoxime proxetil suspension in paediatrics.
    Fujii R
    Drugs; 1991; 42 Suppl 3():57-60. PubMed ID: 1726209
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disposition of orally administered cefpodoxime proxetil in foals and adult horses and minimum inhibitory concentration of the drug against common bacterial pathogens of horses.
    Carrillo NA; Giguère S; Gronwall RR; Brown MP; Merritt KA; O'Kelley JJ
    Am J Vet Res; 2005 Jan; 66(1):30-5. PubMed ID: 15691032
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Physicochemical and pharmacokinetic characterization of a spray-dried cefpodoxime proxetil nanosuspension.
    Gao Y; Qian S; Zhang J
    Chem Pharm Bull (Tokyo); 2010 Jul; 58(7):912-7. PubMed ID: 20606336
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers.
    O'Neill P; Nye K; Douce G; Andrews J; Wise R
    Antimicrob Agents Chemother; 1990 Feb; 34(2):232-4. PubMed ID: 2327771
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of cefpodoxime proxetil with special reference to biochemical parameters, tissue residue, and spermatozoa motility in rats.
    Mujeeb MA; Pardeshi ML
    Indian J Med Sci; 2011 Feb; 65(2):43-9. PubMed ID: 23196312
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Presence of Clostridium difficile and antibiotic and beta-lactamase activities in feces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo.
    Chachaty E; Depitre C; Mario N; Bourneix C; Saulnier P; Corthier G; Andremont A
    Antimicrob Agents Chemother; 1992 Sep; 36(9):2009-13. PubMed ID: 1416894
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.
    Balfour JA; Benfield P
    Pharmacoeconomics; 1996 Aug; 10(2):164-78. PubMed ID: 10163419
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improvement of cefpodoxime proxetil oral absorption in rats by an oil-in-water submicron emulsion.
    Nicolaos G; Crauste-Manciet S; Farinotti R; Brossard D
    Int J Pharm; 2003 Sep; 263(1-2):165-71. PubMed ID: 12954191
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interstitial tissue concentrations of cefpodoxime.
    Liu P; Müller M; Grant M; Webb AI; Obermann B; Derendorf H
    J Antimicrob Chemother; 2002 Jul; 50 Suppl():19-22. PubMed ID: 12077156
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Comparative trial of the clinical efficacy and tolerance of cefatrizine (Cefaperos) and cefpodoxime proxetil (Orelox) in superinfections of chronic obstructive bronchopneumopathies in adults in urban practice].
    Brambilla C; Benhamou D; Guérin JC; Kelkel E; Muir JF; Prud'homme A; Taytard A; Fauche A
    Pathol Biol (Paris); 1995 Nov; 43(9):815-24. PubMed ID: 8746104
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Investigation of factors responsible for low oral bioavailability of cefpodoxime proxetil.
    Kakumanu VK; Arora V; Bansal AK
    Int J Pharm; 2006 Jul; 317(2):155-60. PubMed ID: 16621365
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil.
    Hendrickson JR; North DS
    Ann Pharmacother; 1995 Jun; 29(6):561-5. PubMed ID: 7663025
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics, protein binding, and tissue distribution of orally administered cefpodoxime proxetil and cephalexin in dogs.
    Papich MG; Davis JL; Floerchinger AM
    Am J Vet Res; 2010 Dec; 71(12):1484-91. PubMed ID: 21118001
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infections.
    Cox CE; Graveline JF; Luongo JM
    Drugs; 1991; 42 Suppl 3():41-50. PubMed ID: 1726207
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic study and clinical evaluation of cefpodoxime proxetil in the elderly with impaired renal function.
    Ishioka T
    J Chemother; 1995 Nov; 7 Suppl 4():122-3. PubMed ID: 8904130
    [No Abstract]   [Full Text] [Related]  

  • 59. AS-924, a novel, orally active, bifunctional prodrug of ceftizoxime: physicochemical properties, oral absorption in animals, and antibacterial activity.
    Mori N; Kodama T; Sakai A; Suzuki T; Sugihara T; Yamaguchi S; Nishijima T; Aoki A; Toriya M; Kasai M; Hatano S; Kitagawa M; Yoshimi A; Nishimura K
    Int J Antimicrob Agents; 2001 Nov; 18(5):451-61. PubMed ID: 11711261
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Once-a-day therapy of cefpodoxime proxetil for respiratory tract infections.
    Sawae Y; Ninomiya K; Sumida I; Inoue T; Takaki K; Okada K; Kumagai Y; Ishimaru T; Shimono N; Misumi H
    J Chemother; 1995 Nov; 7 Suppl 4():134-6. PubMed ID: 8904134
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.